Catherine C Coombs
Overview
Explore the profile of Catherine C Coombs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Roeker L, Coombs C, Shah N, Jurczak W, Woyach J, Cheah C, et al.
Acta Haematol
. 2024 Jun;
:1-17.
PMID: 38824917
Introduction: Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor, has demonstrated promising efficacy in B-cell malignancies and is associated with low rates of discontinuation and dose reduction. Pirtobrutinib...
12.
Pham N, Coombs C, OBrien S
Expert Rev Hematol
. 2024 May;
17(4-5):117-126.
PMID: 38693662
Introduction: The therapeutic landscape for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved over the past decade with dramatically improved outcomes with the introduction of targeted therapies. This unfortunately...
13.
Coombs C
Curr Hematol Malig Rep
. 2024 Feb;
19(2):65-74.
PMID: 38337108
Purpose Of Review: The therapeutic landscape for chronic lymphocytic leukemia (CLL) has undergone a complete makeover following the introduction of highly effective targeted therapies, beginning with ibrutinib which first attained...
14.
Johnson S, Haberberger J, Galeotti J, Ramkissoon L, Coombs C, Richardson D, et al.
Leuk Lymphoma
. 2023 Nov;
65(2):209-218.
PMID: 37921062
A large-scale genomic analysis of patients with -mutated myeloid disease has not been performed to date. We reviewed comprehensive genomic profiling results from 6043 adults to characterize clinicopathologic features and...
15.
Easaw S, Ezzati S, Coombs C
Clin Lymphoma Myeloma Leuk
. 2023 Aug;
23(10):697-704.
PMID: 37544810
Over the last decade, targeted inhibition of Bruton's tyrosine kinase (BTK) has led to a paradigm shift in the way chronic lymphocytic leukemia (CLL) is managed. BTK inhibitors (BTKi) are...
16.
Mato A, Woyach J, Brown J, Ghia P, Patel K, Eyre T, et al.
N Engl J Med
. 2023 Jul;
389(1):33-44.
PMID: 37407001
Background: Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options...
17.
Johnson S, Haberberger J, Galeotti J, Ramkissoon L, Coombs C, Richardson D, et al.
Blood Cancer J
. 2023 Jun;
13(1):96.
PMID: 37365170
No abstract available.
18.
Shadman M, Manzoor B, Sail K, Tuncer H, Allan J, Ujjani C, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Apr;
23(7):515-526.
PMID: 37076367
Introduction: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings. Materials And Methods: Using deidentified...
19.
Coombs C, Easaw S, Grover N, OBrien S
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980726
Cellular therapies can be viewed as both the newest and oldest techniques for treating chronic lymphocytic leukemia (CLL) and Richter's transformation (RT). On one hand, allogeneic hematopoietic stem cell transplantation...
20.
Jensen J, Easaw S, Anderson T, Varma Y, Zhang J, Jensen B, et al.
Curr Oncol Rep
. 2023 Mar;
25(5):455-463.
PMID: 36920637
Purpose Of Review: Clonal hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number...